STAT
APRIL 5, 2024
The Centers for Disease Control and Prevention urged medical practitioners on Friday to be on the lookout for people who might have contracted H5N1 bird flu from cows. The agency also urged state health departments to rapidly assess any suspected human cases, and recommended that dairy farms with confirmed or suspected outbreaks require workers to use personal protective equipment.
PharmaVoice
APRIL 3, 2024
AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ALiEM - Pharm Pearls
APRIL 1, 2024
A 23-year-old female with no known past medical history presented with a rash concentrated on her legs, with a few areas on her arms and chest. The rash began the day before presentation when she became overheated while wearing sweatpants in 104°F weather. The rash was mildly pruritic but not painful. She denied any prior reaction to her sweatpants that she has had for several months.
Pharma Times
APRIL 2, 2024
The genetic condition affects one in 279 people in England and significantly increases cancer risk
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 5, 2024
News that H5N1 avian influenza has breached another mammalian species — this time dairy cows — has taken the flu science community aback. Though cows previously had been seen to be susceptible to human flu viruses , and could be experimentally infected with H5 in a lab, the absence of cow involvement until now in H5’s nearly 30-year history lulled scientists into thinking the species was outside the virus’s remit.
PharmaVoice
APRIL 1, 2024
Eledon Therapeutics is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
BioPharma Dive
APRIL 1, 2024
The FDA could soon expand use of two multiple myeloma cell therapies as well as a top-selling medicine from Sanofi and Regeneron, while Pfizer’s years of gene therapy work might finally pay dividends.
STAT
APRIL 5, 2024
Dogs, our sunny, selfless shadows, crave little more than a daily walk, a treat or two, and their human’s happiness. But increasingly, their own happiness is the topic of concern in veterinarian offices, dog parks, and internet forums. Prozac prescriptions for dogs are on the rise, veterinarians across the country acknowledge, along with a myriad of cheaper generic mood stabilizers sold for humans but applied to pets’ separation anxiety, socialization fears, biting habits, or other
PharmaVoice
APRIL 1, 2024
Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.
pharmaphorum
APRIL 2, 2024
Explore the innovative use of artificial intelligence (AI) and machine learning (ML) in securing the pharmaceutical supply chain for resilience and safety. Learn how cutting-edge technology is shaping the future of pharmaceutical logistics.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
APRIL 5, 2024
Hoxa9 and b-catenin molecules are a rare population of self-renewing HSCs found in bone marrow
STAT
APRIL 4, 2024
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease. Relyvrio was approved by the Food and Drug Administration in 2022 , based on data that showed a modest slowing of disease progression. The approval was contentious — regulators initially advised Amylyx not to file for approval until it had conducted another test, but ultimately cleared the drug.
PharmaVoice
APRIL 2, 2024
Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VCs like the Dementia Discovery Fund have invested in the next wave of therapies.
pharmaphorum
APRIL 4, 2024
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug class.
BioPharma Dive
APRIL 5, 2024
The FDA’s clearance comes three weeks after a panel of advisers endorsed expanded use of Abecma despite safety concerns raised by the agency.
STAT
APRIL 4, 2024
It began with injecting monkeys with sewage to see if they developed polio. Building off that early polio work from the 1940s, researchers from the Baylor College of Medicine analyzed public wastewater and showed they could detect over 450 disease-causing viruses. Their study demonstrating the power of sewage as an early-warning system for outbreaks won the 2024 STAT Madness popular vote.
PharmaVoice
APRIL 5, 2024
Infectious diseases that were “off the playing field” are now making a comeback.
pharmaphorum
APRIL 2, 2024
Discover the importance of addressing menopause in the workplace and the benefits of hormone replacement therapy (HRT) through this insightful and informative article on breaking the stigma.
Pharmaceutical Commerce
APRIL 5, 2024
In an interwith with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value and Access Advisor, Schoonveld Advisory, explains why pharmaceutical products tend to cost more in the US than the rest of the world.
STAT
APRIL 4, 2024
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. Some employees may find positions elsewhere in the company, but they are mostly being pulled from the field.
PharmaVoice
APRIL 4, 2024
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
pharmaphorum
APRIL 2, 2024
In a new episode of the pharmaphorum podcast recorded live on site at WIRED Health in London in March, web editor Nicole Raleigh spoke with Elise de Reus, co-founder of Cradle, the generative AI platform that helps scientists to design and program proteins.
Med Ed 101
APRIL 3, 2024
The North American Pharmacist Licensure Examination (NAPLEX) is the clinical exam that allows a pharmacy graduate to become a licensed pharmacist. The NAPLEX is designed to evaluate your knowledge of pharmacy practice and is required for pharmacist licensure. It is a 6-hour exam composed of 225 questions, and students are allowed 5 attempts to pass […] The post What Do The 2023 NAPLEX Pass Rates Mean For 2024?
STAT
APRIL 5, 2024
Johnson & Johnson on Friday announced it would acquire heart device firm Shockwave Medical for $13.1 billion. It’s J&J’s second major deal in the cardiovascular space in two years, following its 2022 purchase of Abiomed for $16.6 billion. Shockwave Medical’s device works to break down calcified plaque in the coronary and peripheral arteries using sonic pressure waves — a treatment called intravascular lithotripsy.
Express Pharma
APRIL 4, 2024
First phase with a builtup area of 29,000 square meters to be completed within a year, second phase by 2026 Gujarat-based SAVA Healthcare conducted the ground-breaking ceremony of its second manufacturing plant, in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC) in March. This green field project will expand the manufacturing capabilities of SAVA Healthcare as well as create 1000+ job opportunities, offering advanced skill development for the local tale
pharmaphorum
APRIL 4, 2024
Last week, pharmaphorum editor-in-chief Jonah Comstock travelled to Philadelphia for Reuters Pharma USA. On today’s podcast, he chats with guest host and Deep Dive editor Eloise McLellan about his biggest takeaways from the two-day event.
FDA Law Blog: Biosimilars
APRIL 2, 2024
By Sara W. Koblitz — Every year, federal agencies submit a budget request to Congress to fund various agency initiatives, and every year FDA includes a list of legislative proposals that it would like to see come out of Congress. This year is no different , and in fact some of the requests on this year’s list are repeat offenders from last year’s. And though FDA may not have gotten everything that it wanted last year, reviewing and reflecting on these lists of legislative proposals provides im
STAT
APRIL 3, 2024
The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, like mental health disorders , Alzheimer’s, and even, as new study results suggest — Parkinson’s disease. In a Phase 2 trial, patients with early Parkinson’s disease taking an older GLP-1 diabetes drug called lixisenatide experienced no worsening of motor symptoms over a year,
Pharma Times
APRIL 3, 2024
The third most common and serious form of cancer affects over 43,000 people every year in the UK
pharmaphorum
APRIL 4, 2024
Healthcare system Providence has spun out a new company, Praia Health, focused on a platform to build and sustain connections between patients and health providers. The new company starts life with $20 million in Series A funding and a mission to develop the Praia Health Identity and Engagement Platform, which was launched within Providence’s digital innovation group (DIG) incubator in 2022 and already handles around 3.5 million user accounts.
Pharmaceutical Commerce
APRIL 2, 2024
In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, explores the two major strategies big pharma companies are employing amid current macro challenges and efforts to offset looming patent losses to blockbuster brands.
STAT
APRIL 4, 2024
On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug , Relyvrio, after a large clinical trial showed that the medicine, approved by the Food and Drug Administration in 2022, was not effective. Amylyx’s co-CEOs, Joshua Cohen and Justin Klee, had previously publicly promised that they would withdraw the drug if further testing failed to show a benefit.
Drug Patent Watch
MARCH 31, 2024
A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States.
pharmaphorum
APRIL 2, 2024
Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Merz. The announcement made last night US time sparked a run on Acorda's shares, down almost 62% at the time of writing. The news emerged shortly after Acorda cancelled its fourth-quarter results conference call, which was scheduled to take place yesterday.
Med Ed 101
MARCH 31, 2024
The Kidney Disease: Improving Global Outcomes (KDIGO) organization has released an updated April 2024 clinical practice guideline for the evaluation and management of Chronic Kidney Disease (CKD). The new 2024 KDIGO guidelines include 6 chapters dedicated to the evaluation of CKD, risk assessment in people with CKD, management to delay CKD progression and manage its […] The post 2024 KDIGO Guidelines: The MOST Important Medication Recommendations appeared first on Med Ed 101.
Expert insights. Personalized for you.
364 
Let's personalize your content